{"id":"ascs-cx401-company-code","safety":{"commonSideEffects":[{"rate":null,"effect":"Application site reactions"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Wound deterioration"}]},"_chembl":{"chemblId":"CHEMBL5747601","moleculeType":null,"molecularWeight":"490.61"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cx401 consists of expanded allogeneic adipose-derived stem cells (ASCs) that are applied topically to chronic diabetic foot ulcers. These cells are believed to work through paracrine signaling, secreting anti-inflammatory cytokines and growth factors that promote angiogenesis, reduce inflammation, and enhance wound healing. The mechanism leverages the immunomodulatory and regenerative properties of mesenchymal stem cells to improve tissue repair in non-healing wounds.","oneSentence":"Cx401 is an allogeneic adipose-derived mesenchymal stem cell therapy that promotes tissue repair and reduces inflammation in chronic wounds.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:42:08.902Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic diabetic foot ulcers"}]},"trialDetails":[{"nctId":"NCT01020825","phase":"","title":"Long-term Safety and Efficacy of Adipose-derived Stem Cells to Treat Complex Perianal Fistulas in Patients Participating in the FATT-1 Randomized Controlled Trial","status":"COMPLETED","sponsor":"Tigenix S.A.U.","startDate":"2008-09","conditions":"Complex Perianal Fistula","enrollment":148},{"nctId":"NCT00475410","phase":"PHASE3","title":"Efficacy and Safety of Adipose Stem Cells to Treat Complex Perianal Fistulas Not Associated to Crohn´s Disease","status":"COMPLETED","sponsor":"Tigenix S.A.U.","startDate":"2007-02","conditions":"Anal Fistula","enrollment":214},{"nctId":"NCT01378390","phase":"PHASE3","title":"Safety and Efficacy of Adipose-Derived Stem Cells to Treat Complex Perianal Fistulas Patients With Crohn's Disease","status":"TERMINATED","sponsor":"Tigenix S.A.U.","startDate":"2008-12","conditions":"Complex Perianal Fistula, Crohn Disease","enrollment":56}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"ASCs (Cx401, company code)","genericName":"ASCs (Cx401, company code)","companyName":"Tigenix S.A.U.","companyId":"tigenix-s-a-u","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cx401 is an allogeneic adipose-derived mesenchymal stem cell therapy that promotes tissue repair and reduces inflammation in chronic wounds. Used for Chronic diabetic foot ulcers.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}